TIDMAGL
RNS Number : 9807D
Angle PLC
06 February 2018
For immediate release 6 February 2018
ANGLE plc ("the Company")
RESEARCH GRANT FROM ABBOTT
Abbott PathVysion HER-2 DNA Probe assay to be used in ANGLE FDA
Study
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy
company, is delighted to announce that it has signed an agreement
with global healthcare company Abbott in which Abbott will supply
ANGLE with its proprietary PathVysion(TM) HER-2 DNA FISH Probe kits
for ANGLE's ANG-002 FDA study for FISH (fluorescence in situ
hybridization) analysis of circulating tumor cells (CTCs) in the
form of a research grant.
FISH analysis, which is a form of investigation of the cancer
cells used with solid tissue biopsy to help select treatment, is
one of the exploratory end-points for ANGLE's FDA study in
metastatic breast cancer. The objective of this end-point is to
demonstrate that CTCs can be harvested from the blood of metastatic
breast cancer patients using the Parsortix(TM) system and that the
harvested CTCs can then be subjected to FISH analysis to determine
their HER-2 status.
Abbott's PathVysion HER-2 DNA FISH Probe Kit (PathVysion) is one
of the first examples of what is recognised as genomic disease
management (or personalised medicine). Physicians use the
PathVysion HER-2 result to help determine which patients may be the
best candidates for personalised therapy. Specifically, PathVysion
accurately determines HER-2 gene status, identifying which patients
are HER-2 positive. About 1 in every 5 breast cancer patients have
a positive HER-2 result and for these women, it means they are more
likely to respond to Herceptin(R) therapy. Herceptin can help
control the growth of cancer cells that contain high amounts of
HER-2 (human epidermal growth factor receptor 2). Herceptin works
by blocking the effects of HER-2 and encouraging the immune system
(the body's natural defences) to attack and kill the cancer
cells.
Abbott's PathVysion was released in 1998 and was the first
gene-based test approved (2001) by the FDA for determining HER-2
status. Abbott remains the global market leader for FISH testing in
solid tissue biopsies. A positive PathVysion HER-2 result in
Parsortix harvested CTCs would demonstrate feasibility of
evaluating use of the assay in a breast cancer liquid biopsy in
metastatic breast cancer patients. This would be a significant step
toward advancing healthcare options for these patients, as it is
not often possible to obtain solid tumor biopsy specimens in late
stage cancer and the patient's HER-2 status can change with disease
progression. Using blood as a surrogate could provide an avenue to
new therapies and new hope for a very ill population.
Kathryn B Becker, PhD, Franchise Director Oncology and Companion
Diagnostics, Abbott commented:
"Abbott is pleased to collaborate with ANGLE in this important
evaluation of PathVysion in liquid biopsy specimens. The PathVysion
HER-2 DNA FISH Probe kit is reliable and accurate in tissue biopsy
samples and the Parsortix system may unlock the potential for
PathVysion use in a simple blood test. We look forward to the
outcomes of the study and the potential opportunity to further
collaborate with ANGLE in combining FISH and liquid biopsy in other
areas."
ANGLE's Founder and Chief Executive, Andrew Newland, added:
"This is another important collaboration for ANGLE with a leader
in downstream analysis. Abbott's PathVysion is the market leader
for FISH evaluation of HER-2 in breast cancer. Following our FDA
studies, we hope to be able to work with Abbott to extend
PathVysion use into routine blood test analysis as an important
downstream application of the Parsortix system in breast cancer.
Use of ANGLE's Parsortix system would for the first time enable
established tissue biopsy techniques to be used for breast cancer
on cancer cells obtained from a simple blood test protecting
patients from invasive procedures and improving their care whilst
at the same time reducing healthcare costs."
For further information ANGLE:
ANGLE plc +44 (0) 1483 343434
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
finnCap Ltd (NOMAD and Joint
Broker)
Corporate Finance - Adrian
Hargrave, Simon Hicks, Kate
Bannatyne
Corporate Broking - Alice Lane,
Nikita Jain +44 (0)20 7220 0500
WG Partners (Joint Broker)
Nigel Barnes, Nigel Birks,
Andrew Craig, Chris Lee +44 (0) 203 705 9330
FTI Consulting
Simon Conway, Mo Noonan, Stephanie
Cuthbert +44 (0) 203 727 1000
Kimberly Ha (US) +1 212 850 5612
For Frequently Used Terms, please see the Company's website on
http://www.angleplc.com/the-parsortix-system/glossary/
This announcement contains inside information.
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a world leading liquid biopsy company with sample to
answer solutions. ANGLE's proven patent protected platforms include
an epitope-independent circulating tumor cell (CTC) harvesting
technology and a downstream analysis system for cost effective,
highly multiplexed analysis of nucleic acids and proteins.
ANGLE's cell separation technology is called the Parsortix(TM)
system and it enables a liquid biopsy (simple blood test) to be
used to provide the cells of interest. Parsortix is the subject of
granted patents in Europe, the United States, Canada, India, China,
Japan and Australia and three extensive families of patents are
being progressed worldwide. The system is based on a microfluidic
device that captures live cells based on a combination of their
size and compressibility. The Parsortix system has a CE Mark for
Europe and FDA clearance is in process for the United States.
ANGLE's analysis technology for proteins and nucleic acids of
all types is based on a patented flow through array technology. It
provides for highly multiplexed, rapid and sensitive capture of
targets from a wide variety of sample types. A proprietary
chemistry allows for the capture and amplification of over 100
biomarkers simultaneously in a single reaction. These technologies
can be combined to provide fully automated, sample to answer
results in both centralised laboratory and point of use cartridge
formats. It is ideal for measuring gene expression and other
markers directly from Parsortix harvests.
ANGLE has established formal collaborations with world-class
cancer centres. These Key Opinion Leaders are working to identify
applications with medical utility (clear benefit to patients), and
to secure clinical data that demonstrates that utility in patient
studies. Details are available here
http://www.angleplc.com/the-company/collaborators/
The analysis of the cells that can be harvested from patient
blood with ANGLE's Parsortix system has the potential to help
deliver personalised cancer care offering profound improvements in
clinical and health economic outcomes in the treatment and
diagnosis of various forms of cancer.
The global increase in cancer to a 1 in 3 lifetime incidence is
set to drive a multi-billion dollar clinical market. The Parsortix
system is designed to be compatible with existing major medtech
analytical platforms and to act as a companion diagnostic for major
pharma in helping to identify patients that will benefit from a
particular drug and then monitoring the drug's effectiveness.
As well as cancer, the Parsortix technology has the potential
for deployment with several other important cell types in the
future. ANGLE biomarker analysis platforms are adaptable to measure
protein and nucleic acid biomarkers across the full spectrum of
disease applications.
ANGLE stock trades on the AIM market of the London Stock
Exchange under the ticker symbol AGL and in New York on the OTC-QX
under the ticker symbol ANPCY. For further information please
visit: www.angleplc.com
About Abbott www.abbott.com
Abbott is a global healthcare company devoted to improving life
through the development of products and technologies that span the
breadth of healthcare. With a portfolio of leading, science-based
offerings in diagnostics, medical devices, nutritionals and branded
generic pharmaceuticals, Abbott serves people in more than 150
countries and employs approximately 99,000 people.
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGRBCGDDRSGBGIU
(END) Dow Jones Newswires
February 06, 2018 02:00 ET (07:00 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2023 to Apr 2024